Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors.

Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors.

Invariant human TCR Valpha24-Jalpha18+/Vbeta11+ NKT cells (iNKT) are restricted by CD1d-alpha-glycosylceramides. We analyzed crystal structures and binding characteristics for an iNKT TCR plus two CD1d-alpha-GalCer-specific Vbeta11+ TCRs that use different TCR Valpha chains. The results were similar...

Full description

Bibliographic Details
Main Authors:	Gadola, S, Koch, M, Marles-Wright, J, Lissin, N, Shepherd, D, Matulis, G, Harlos, K, Villiger, P, Stuart, D, Jakobsen, B, Cerundolo, V, Jones, E
Format:	Journal article
Language:	English
Published:	2006

Similar Items

The crystal structure of human CD1d with and without alpha-galactosylceramide.
by: Koch, M, et al.
Published: (2005)

Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes.
by: Gadola, S, et al.
Published: (2002)

Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.
by: Denkberg, G, et al.
Published: (2008)

Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice
by: Takahiro Uchida, et al.
Published: (2018-05-01)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
by: Besra Gurdyal S, et al.
Published: (2008-12-01)

Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains.
by: Gadola, S, et al.
Published: (2002)

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
by: Shailbala Singh, et al.
Published: (2014-10-01)

Alpha-galactosylceramide (αGalCer) enhances vaccine-induced protection in a model of ricin intoxication
by: Jennifer L. Yates, et al.
Published: (2018-08-01)

Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop.
by: Gediminas Matulis, et al.
Published: (2010-06-01)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
by: Lisa A. King, et al.
Published: (2018-07-01)

Generation of CD1 tetramers as a tool to monitor glycolipid-specific T cells.
by: Gadola, S, et al.
Published: (2003)

Time-course analysis of liver and serum galectin-3 in acute liver injury after alpha-galactosylceramide injection
by: Mikiko Matsuo, et al.
Published: (2024-01-01)

Time-course analysis of liver and serum galectin-3 in acute liver injury after alpha-galactosylceramide injection.
by: Mikiko Matsuo, et al.
Published: (2024-01-01)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
by: Lianjun Zhang, et al.
Published: (2017-11-01)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
by: Lisa A. King, et al.
Published: (2018-11-01)

The crystal structure of human CD1b with a bound bacterial glycolipid.
by: Batuwangala, T, et al.
Published: (2004)

Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+ T Cells
by: Roberta Manco, et al.
Published: (2023-03-01)

Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis
by: Satoshi Suzuki, et al.
Published: (2019-07-01)

Crystal structure of the CD2-binding domain of CD58 (lymphocyte function-associated antigen 3) at 1.8-A resolution.
by: Ikemizu, S, et al.
Published: (1999)

Depletion of Thymus-Derived CD4+CD25+ T Cells Abrogates the Suppressive Effects of α-galactosylceramide Treatment on Experimental Allergic Conjunctivitis
by: Atsuki Fukushima, et al.
Published: (2008-01-01)

The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines
by: Liu Y, et al.
Published: (2021-01-01)

Structure of a complex of CD47 and the paired receptor SIRP alpha reveals a mechanism for ligand discrimination
by: Hatherley, D, et al.
Published: (2008)

Vectorized Delivery of Alpha-GalactosylCeramide and Tumor Antigen on Filamentous Bacteriophage fd Induces Protective Immunity by Enhancing Tumor-Specific T Cell Response
by: Rossella Sartorius, et al.
Published: (2018-06-01)

Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2.
by: Gao, G, et al.
Published: (1997)

The structure of the macrophage signal regulatory protein alpha (SIRPalpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors.
by: Hatherley, D, et al.
Published: (2007)

The PGRMC1 Antagonist AG-205 Inhibits Synthesis of Galactosylceramide and Sulfatide
by: Lihua Wang-Eckhardt, et al.
Published: (2021-12-01)

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
by: Bianca L. Artiaga, et al.
Published: (2022-08-01)

Efficient synthesis of α-galactosylceramide and its C-6 modified analogs
by: Huiting Li, et al.
Published: (2022-11-01)

Production of α-galactosylceramide by a prominent member of the human gut microbiota.
by: Laura C Wieland Brown, et al.
Published: (2013-07-01)

Structural studies on determinants of receptor/ligand binding in the tumour necrosis factor and T cell receptor protein families
by: Marles-Wright, J
Published: (2005)

Structural studies on determinants of receptor/ligand binding in the tumour necrosis factor and T cell receptor protein families
by: Marles-Wright, J
Published: (2005)

The molecular basis for recognition of CD1d/α-galactosylceramide by a human non-Vα24 T cell receptor.
by: Jacinto López-Sagaseta, et al.
Published: (2012-01-01)

Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
by: Michael Nowak, et al.
Published: (2010-06-01)

Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d
by: Katharine Clark, et al.
Published: (2019-10-01)

Galactosylceramide containing omega-amino-fatty acids: preparation, characterization, and sulfotransferase acceptor.
by: K Kamio, et al.
Published: (1992-08-01)

Some lessons from the systematic production and structural analysis of soluble (alpha)(beta) T-cell receptors.
by: van Boxel, G, et al.
Published: (2009)

Structural and functional aspects of lipid binding by CD1 molecules.
by: Silk, J, et al.
Published: (2008)

Characterization of a Glycolipid Synthase Producing α-Galactosylceramide in <i>Bacteroides fragilis</i>
by: Marc Caballé, et al.
Published: (2022-11-01)

Antimalarial Activity of Axidjiferosides, New β-Galactosylceramides from the African Sponge Axinyssa djiferi
by: Gilles Barnathan, et al.
Published: (2013-04-01)

Bacterial immunogenic α-galactosylceramide identified in the murine large intestine: dependency on diet and inflammation
by: Johanna von Gerichten, et al.
Published: (2019-11-01)